Inherited Metabolic Disorders-Pipeline Insights, 2014

LONDON, Aug. 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Inherited Metabolic Disorders-Pipeline Insights, 2014

https://www.reportbuyer.com/product/2278597/-Inherited-Metabolic-Disorders-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Inherited Metabolic Disorders-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Inherited Metabolic Disorders. This report provides information on the therapeutic development based on the Inherited Metabolic Disorders dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Inherited Metabolic Disorders
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Inherited Metabolic Disorders pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Inherited Metabolic Disorders and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Inherited Metabolic Disorders
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Inherited Metabolic Disorders pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Inherited Metabolic Disorders Overview
- Inherited Metabolic Disorders Pipeline Therapeutics
- Inherited Metabolic Disorders Therapeutics under Development by Companies
- Inherited Metabolic Disorders Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Inherited Metabolic Disorders Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Inherited Metabolic Disorders Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Inherited Metabolic Disorders Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Inherited Metabolic Disorders – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Inherited Metabolic Disorders – Discontinued Products
- Inherited Metabolic Disorders – Dormant Products
- Companies Involved in Therapeutics Development for Inherited Metabolic Disorders
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Inherited Metabolic Disorders, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Inherited Metabolic Disorders Assessment by Monotherapy Products
- Inherited Metabolic Disorders Assessment by Combination Products
- Inherited Metabolic Disorders Assessment by Route of Administration
- Inherited Metabolic Disorders Assessment by Stage and Route of Administration
- Inherited Metabolic Disorders Assessment by Molecule Type
- Inherited Metabolic Disorders Assessment by Stage and Molecule Type
- Inherited Metabolic Disorders Therapeutics – Discontinued Products
- Inherited Metabolic Disorders Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Inherited Metabolic Disorders, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Inherited Metabolic Disorders Assessment by Monotherapy Products
- Inherited Metabolic Disorders Assessment by Combination Products
- Inherited Metabolic Disorders Assessment by Route of Administration
- Inherited Metabolic Disorders Assessment by Stage and Route of Administration
- Inherited Metabolic Disorders Assessment by Molecule Type
- Inherited Metabolic Disorders Assessment by Stage and Molecule Type

Read the full report:
Inherited Metabolic Disorders-Pipeline Insights, 2014

https://www.reportbuyer.com/product/2278597/-Inherited-Metabolic-Disorders-Pipeline-Insights-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer